» Articles » PMID: 36477448

Structural Basis for the Non-self RNA-activated Protease Activity of the Type III-E CRISPR Nuclease-protease Craspase

Overview
Journal Nat Commun
Specialty Biology
Date 2022 Dec 8
PMID 36477448
Authors
Affiliations
Soon will be listed here.
Abstract

The RNA-targeting type III-E CRISPR-gRAMP effector interacts with a caspase-like protease TPR-CHAT to form the CRISPR-guided caspase complex (Craspase), but their functional mechanism is unknown. Here, we report cryo-EM structures of the type III-E gRAMP and gRAMP-TPR-CHAT complexes, before and after either self or non-self RNA target binding, and elucidate the mechanisms underlying RNA-targeting and non-self RNA-induced protease activation. The associated TPR-CHAT adopted a distinct conformation upon self versus non-self RNA target binding, with nucleotides at positions -1 and -2 of the CRISPR-derived RNA (crRNA) serving as a sensor. Only binding of the non-self RNA target activated the TPR-CHAT protease, leading to cleavage of Csx30 protein. Furthermore, TPR-CHAT structurally resembled eukaryotic separase, but with a distinct mechanism for protease regulation. Our findings should facilitate the development of gRAMP-based RNA manipulation tools, and advance our understanding of the virus-host discrimination process governed by a nuclease-protease Craspase during type III-E CRISPR-Cas immunity.

Citing Articles

Structural basis for regulation of a CBASS-CRISPR-Cas defense island by a transmembrane anti-σ factor and its ECF σ partner.

Bernal-Bernal D, Pantoja-Uceda D, Lopez-Alonso J, Lopez-Rojo A, Lopez-Ruiz J, Galbis-Martinez M Sci Adv. 2024; 10(43):eadp1053.

PMID: 39454004 PMC: 11506125. DOI: 10.1126/sciadv.adp1053.


Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: A comprehensive review and future prospects.

Rajanathadurai J, Perumal E, Sindya J Funct Integr Genomics. 2024; 24(5):164.

PMID: 39292321 DOI: 10.1007/s10142-024-01455-3.


Structural basis of negative regulation of CRISPR-Cas7-11 by TPR-CHAT.

Hong T, Luo Q, Ma H, Wang X, Li X, Shen C Signal Transduct Target Ther. 2024; 9(1):111.

PMID: 38735995 PMC: 11089037. DOI: 10.1038/s41392-024-01821-4.


Development of Single Molecule Techniques for Sensing and Manipulation of CRISPR and Polymerase Enzymes.

Chu J, Romero A, Taulbee J, Aran K Small. 2023; 19(38):e2300328.

PMID: 37226388 PMC: 10524706. DOI: 10.1002/smll.202300328.

References
1.
Koonin E, Aravind L . Origin and evolution of eukaryotic apoptosis: the bacterial connection. Cell Death Differ. 2002; 9(4):394-404. DOI: 10.1038/sj.cdd.4400991. View

2.
Kazlauskiene M, Tamulaitis G, Kostiuk G, Venclovas C, Siksnys V . Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition. Mol Cell. 2016; 62(2):295-306. DOI: 10.1016/j.molcel.2016.03.024. View

3.
Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S . CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007; 315(5819):1709-12. DOI: 10.1126/science.1138140. View

4.
Jia N, Mo C, Wang C, Eng E, Marraffini L, Patel D . Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity. Mol Cell. 2018; 73(2):264-277.e5. PMC: 6355164. DOI: 10.1016/j.molcel.2018.11.007. View

5.
Lupardus P, Shen A, Bogyo M, Garcia K . Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science. 2008; 322(5899):265-8. PMC: 3272704. DOI: 10.1126/science.1162403. View